BLU-5937：About BLU
About BLU
A 24
https://classic.clinicaltrials
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained ...
A 52
https://www.templehealth.org
Overview. This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
A Dose Escalation Study of BLU
https://www.mayo.edu
The purpose of this study is to demonstrate the effectiveness and safety of multiple doses of BLU-5937 in adults suffering from RCC. The study will help ...
BLU-5937
https://pubmed.ncbi.nlm.nih.go
BLU-5937 is a small molecule that was shown to be a potent, selective and non-competitive P2X3 homotrimeric receptor antagonist.
Camlipixant (BLU
https://www.medchemexpress.com
Camlipixant (BLU-5937) a potent, selective, non-competitive and orally active P2X3 homotrimeric receptor antagonist with an IC50 of 25 nM against hP2X3 ...
Efficacy in SOOTHE
https://erj.ersjournals.com
Efficacy in SOOTHE, A Phase 2b Trial of BLU-5937 In Refractory Chronic Cough, Was Not Dependant of Taste Disturbance Adverse Events · Abstract · Jump To.
Will This Chronic Cough Drug Succeed Where Others ...
https://www.medpagetoday.com
Two patients receiving the highest BLU-5937 dose withdrew because of adverse effects, as did one placebo recipient. Following Smith's ...